Terms: = Lung cancer AND uPA AND Clinical Outcome
3 results:
1. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and upa expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract] [Full Text] [Related]
2. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
Blumenschein GR; Reck M; Fossella F; Stewart DJ; Lathia C; Peña C
Cancer Biomark; 2011-2012; 10(6):287-98. PubMed ID: 22820084
[TBL] [Abstract] [Full Text] [Related]
3. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone.
Gamberi G; Benassi MS; Ragazzini P; Pazzaglia L; Ponticelli F; Ferrari C; Balladelli A; Mercuri M; Gigli M; Bertoni F; Picci P
Ann Oncol; 2004 Mar; 15(3):498-503. PubMed ID: 14998856
[TBL] [Abstract] [Full Text] [Related]
